September 1, 2009 (FinancialWire) — Scolr Pharma, Inc. (AMEX: DDD) has appointed Stephen J. Turner as its chief executive officer and president. The employment of Bruce S. Morra in these positions terminated on August 28 by mutual agreement, according to the company.

Turner has been VP and chief technical officer of Scolr since 2003 and has been involved in development of the company’s controlled delivery technology Turner said “Scolr plans to continue efforts to license our 12 hour 600 mg ibuprofen formulation and we are advancing discussions with potential partners.”

Morra will continue to serve as a director of the company.

Bothell, Washington-based Scolr Pharma is a specialty pharmaceutical company whose objective is to combine its formulation focus and its CDT platform to develop novel pharmaceutical, over-the-counter, and nutritional products.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.